TG Therapeutics announced a collaboration with actress Christina Applegate, who has lived with MS for 5 years, to raise awareness and support meaningful conversations for people living with multiple sclerosis. The partnership launched a new platform called www.NextInMS.com during Super Bowl LX, featuring Christina's personal perspectives and expert educational content designed to foster open dialogue among MS patients, caregivers, and healthcare professionals.

U.S. stock futures declined on Wednesday as investors await a Supreme Court ruling on Trump's tariff authority. The Consumer Price Index rose 2.7% year-over-year in December, matching expectations, while core CPI came in slightly below forecasts at 2.6%. Major indices including the Dow Jones, S&P 500, and Nasdaq 100 all declined in premarket trading. Notable movers include Wells Fargo reporting earnings, BP announcing a $5 billion writedown in energy transition businesses, WeRide launching a robotaxi service on WeChat, and TG Therapeutics providing optimistic 2026 guidance.

TG Therapeutics' CEO Michael S. Weiss will participate in a virtual fireside chat at the TD Cowen Immunology & Inflammation Summit on November 12, 2025, discussing the company's developments in B-cell disease treatments.

TG Therapeutics reported strong Q2 2025 results with BRIUMVI sales growth, raising full-year revenue guidance to $585 million. The company is focusing on expanding product reach, developing new dosing regimens, and exploring additional indications for its multiple sclerosis therapy.

TG Therapeutics reported strong Q1 2025 financial results for its multiple sclerosis drug BRIUMVI, with $119.7 million in U.S. net sales and raised its full-year revenue guidance. The company also provided updates on its pipeline, including plans to advance subcutaneous BRIUMVI and a new therapy for progressive MS.

Several mid-cap stocks, including Bilibili, MARA Holdings, and ZEEKR Intelligent Technology, saw significant gains last week. The article highlights the top 8 mid-cap gainers and discusses the reasons behind their performance.

TG Therapeutics, a biopharmaceutical company, announced that its Chairman and CEO will participate in the 7th Annual Evercore HealthCONx Conference on December 3-5, 2024. The company has received FDA and European approvals for its multiple sclerosis treatment BRIUMVI.

TG Therapeutics, a biopharmaceutical company, was ranked the fastest-growing company in North America on the 2024 Deloitte Technology Fast 500 list. This growth was driven by the success of their multiple sclerosis drug BRIUMVI, which was approved in 2022.

Our first-ever twin bill.

Fireside chat scheduled for Tuesday, June 11, 2024, at 1:20 PM ET Fireside chat scheduled for Tuesday, June 11, 2024, at 1:20 PM ET

Fireside chat scheduled for Wednesday, June 5, 2024, at 1:30 PM ET Fireside chat scheduled for Wednesday, June 5, 2024, at 1:30 PM ET

NEW YORK, May 31, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting study designs for post-marketing studies being undertaken for BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting. Presentations are now public and can be viewed using the below links.